- Fava, Maurizio, MD;
- Freudenreich, Oliver, MD, FAPM;
- Ghaznavi, Sharmin, MD, PhD;
- Nierenberg, Andrew, MD;
- Ongür, Dost, MD, PhD
Early detection of bipolar disorder and schizophrenia are critical to optimizing outcomes for patients. Yet these conditions present many diagnostic and clinical challenges for mental health professionals.
We developed these free sessions to help mental health professionals address these important issues. They focus on early detection, treatment and management of bipolar disorder, depression and schizophrenia. The sessions were recorded during a one-day conference in Boston in January 2015. All are led by senior faculty from the Massachusetts General Hospital Department of Psychiatry.
- Assessment strategies for bipolar disorder, depression and schizophrenia
- Risk factors for metabolic abnormalities
- Interventions for metabolic problems
- Effective pharmacologic treatments for fatigue and cognitive dysfunction in depression
This activity is part of a free series. All the activities help you effectively assess and treat bipolar disorder, depression, schizophrenia, and related conditions such as fatigue and cognitive dysfunction.
View the other activities in the series: Massachusetts General Hospital Colloquium: Common Challenges in the Treatment of Mood Disorders and Schizophrenia
- Identify early or prodromal signs and symptoms of bipolar disorder and schizophrenia.
- Demonstrate effective treatment strategies for affective and psychotic symptoms in bipolar disorder and schizophrenia.
- Identify patient risk factors for metabolic abnormalities, institute periodic monitoring regimens for antipsychotic-induced metabolic side effects, and describe methods to prevent or minimize metabolic problems.
- Employ appropriate pharmacologic treatments to treat fatigue and cognitive dysfunction in patients with depression.
Massachusetts General Hospital Colloquium: Common Challenges in the
Treatment of Mood Disorders and Schizophrenia Online Series
Archived Lectures from
Saturday, January 24, 2015
Wyndham Beacon Hill, Boston, MA
1 hour 15 minutes
Early Detection and Intervention in Bipolar Disorder and Schizophrenia
1 hour 15 minutes
Optimal Treatment of Psychosis in Bipolar Disorder
1 hour 15 minutes
Assessment and Treatment of Affective Symptoms in Schizophrenia
1 hour 15 minutes
Long-Acting Injectable (LAI) Antipsychotics in Bipolar Disorder and Schizophrenia
1 hour 15 minutes
Assessing and Managing Metabolic Risk in Bipolar Disorder and Schizophrenia
1 hour 15 minutes
Overview: Limitations of Current Treatment of Depression
Director, Division of Clinical Research of the MGH Research Institute
Executive Vice Chair, Department of Psychiatry
Executive Director, Clinical Trials Network & Institute (CTNI)
Massachusetts General Hospital
Associate Dean for Clinical & Translational Research
Slater Family Professor of Psychiatry
Harvard Medical School
Co-Director, MGH Schizophrenia Clinical and Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Assistant in Psychiatry, Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School
Thomas P. Hackett, MD, Endowed Chair in Psychiatry
Director, Dauten Family Center for Bipolar Treatment Innovation
Associate Director, Depression Clinical and Research Program
Director, Training and Education, MGH Research Institute
Massachusetts General Hospital
Professor of Psychiatry, Harvard Medical School
Clinical Director of Psychotic Disorders Division, McLean Hospital
Assistant Professor of Psychiatry, Harvard Medical School
This course has been designed for:
- Primary Care Physicians
- Physician Assistants
This program has received support in the form of educational grants from Janssen Global Services, LLC, Sunovion Pharmaceuticals, Inc., and Takeda Pharmaceuticals International, Inc.
Release Date: September 15, 2015
Expiration Date: September 15, 2018
Last Review Date: February 14, 2018 by Robert Althoff, MD
AMA PRA Category 1 CreditTM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.
McLean Hospital designates this enduring material for a maximum of 7.5AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Psychologists CE Credit
The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.
This offering meets the criteria for 7.5 continuing education credits for psychologists.
Nursing Contact Hours
Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.
This program meets the requirements of the Massachusetts Board of Registration in Nursing at (244 CMR 5.00) for 7.5 contact hours of nursing continuing education credit.
Other Providers can claim a Participation Certificate upon successful completion of this course.
Participation Certificates will specify the title, location, type of activity, date of activity, and number ofAMA PRA Category 1 CreditsTMassociated with the activity. Providers should check with their regulatory agencies to determine ways in whichAMA PRA Category 1 CreditsTMmay or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.
Tristan Gorrindo, MD, course director
Maurizio Fava, MD, course director
Andrew A. Nierenberg, MD, course director
David H. Rubin, MD, reviewer
Jane Pimental, MPH
Susan E. Sprich, PhD, psychologist reviewer
Michael Hirsch, MD
In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:
The ACCME defines a "commercial interest" as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines "'relevant' financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:
Maurizio Fava, MD,Course Director
Research Support: Abbot Laboratories; Alkermes, Inc.; American Cyanamid;Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite LLC;PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Wyeth-Ayerst Laboratories
Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.;RCT Logic, LLC ( formerly Clinical Trials Solutions, LLC); Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.
Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories
Equity Holdings/Royalty/Patent Income: Compellis; PsyBrain, Inc. Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to Pharmaceutical Product Development, LLC (PPD); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD). Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte.Ltd.
Susan E. Sprich, PhD, Psychologist reviewer
Royalties:Oxford University Press (for co-authoring treatment manual and client workbook), Springer (for editing book)
Michael Hirsch, MD,Planner
Royalties: UpToDate Inc. (medical writing)
Andrew A. Nierenberg, MD, Course Director
Consultant: Abbott Laboratories, American Psychiatric Association, Appliance Computing Inc. (Mindsite), Basliea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaissance, Genentech, GlaxoSmithKline, Hoffman LaRoche, Infomedic, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, Naurex, Novartis, PamLabs, Pfizer, PGx Health, Ridge Diagnostics Shire, Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept, and Teva; consulted through the MGH Clinical Trials Network and Institute (CTNI) for Astra Zeneca, Brain Cells, Inc, Dianippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering-Plough, Targacept and Takeda/Lundbeck Pharmaceuticals.
Grants/Research Support: American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst.
Honoraria: Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, International Society for Bipolar Disorder, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing and Wolters Klower Publishing.
Stock: Appliance Computing, Inc. (MindSite); Brain Cells, Inc., Medavante
Copyrights: Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI).
Oliver Freudenreich, MD, FAPM
Research Grant: Psychogenics, Forum
Honoraria: Global Medical Education, MEDIQ, Oakstone Medical Education, UpToDate, BeaconHealth Strategies, Optimal Medicine
Dost Ongur, MD, PhD
Scientific Advisory Board: Lilly Inc.
Research Funding: Roche Genentech
All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.
Policy on Faculty and Provider Disclosure
It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.
This program has received support in the form of educational grants from
- Janssen Global Services, LLC
- Sunovion Pharmaceuticals, Inc.
- Takeda Pharmaceuticals International, Inc.
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit